Liam Brown retweeted
NHMRC-funded researchers, led by @Dr_Shuai_Li are leading the way in advancing breast cancer risk assessment by uncovering hidden insights within digital mammograms.
Read more from last year’s 10 of the Best publication: nhmrc.gov.au/about-us/news-c…
Sweet! Looks like a great opportunity for junior faculty to get started with clinical trials - I'm definitely going to register for that webinar!.
🚨Interested in getting involved in clinical trials as junior faculty?
Join our @ASCO #IMGCoP Webinar to learn about opportunities in IITs, cooperative groups & industry-sponsored trials!
📅 Oct 30 | 7 PM ET
🔗 tinyurl.com/bhdf788h
@ASCOTECAG @HemOncFellows #MedEd #MedX
I'd love to learn more about the various opportunities available!.
🚨Interested in getting involved in clinical trials as junior faculty?
Join our @ASCO #IMGCoP Webinar to learn about opportunities in IITs, cooperative groups & industry-sponsored trials!
📅 Oct 30 | 7 PM ET
🔗 tinyurl.com/bhdf788h
@ASCOTECAG @HemOncFellows #MedEd #MedX
Liam Brown retweeted
Researchers investigated the impact of TET2-driven clonal hematopoiesis of indeterminate potential on inflammatory bone loss and identified inflammatory bone loss associated with increased tissue infiltration of neutrophils, monocytes, and Th17cells. ow.ly/V2QS5101sKt.
ALT Cell population alterations in the gingiva and systemic tissues in TET2-driven CHIP. Lethally irradiated CD45.1 mice were transplanted with either 10% Tet2–/– CD45.2 BM cells and 90% WT CD45.1 BM cells (“10% Tet2–/– BMT” group) or with 10% Tet2+/+ CD45.2 BM cells and 90% WT CD45.1 cells (“10% Tet2+/+ BMT” group).
Wow, so excited to see some promising breakthroughs in GIST treatment!.
#SebastianBauer presented on behalf of investigators of #StrateGIST1 study on role #velzatinib of #molecularresponse in KIT ctDNA in response - confirming rapid disease control associated with clinical response.
Exciting times in novel therapeutic options for GISTs!
#Sarcoma #drugdevelopment @ctosociety #ESMO26 #ESMOAmbassadors @myESMO
We need to rethink our diagnostic approaches and move quickly early recognition is key!".
🫀From Healthy Atria to Atrial Failure: Rethinking Atrial Cardiomyopathy (AtCM) from the #HFA_ESC clinical consensus statement:
📍AtCM extends beyond #AF: Electrical, mechanical & structural abnormalities may precede clinically apparent AF or #HeartFailure
📍Diagnosis: Electrical atrial dysfunction (P-wave score ≥1) PLUS ≥1 of: mechanical dysfunction, atrial enlargement or excessive atrial fibrosis
📍Proposed diagnostic thresholds:
- P-wave ≥120 ms (standard ECG) or ≥150 ms (amplified ECG)
- Advanced interatrial block: P-wave ≥120 ms + biphasic morphology in ≥2 inferior leads
- LA reservoir strain <23%
- LAVi >40 mL/m² (>48 mL/m² in women >65 years)
- Atrial fibrosis: thresholds pending validation
📍New P-wave scoring system (0–4): Ranges from normal P-wave (0), prolonged P-wave (1), advanced interatrial block without (2) or with paroxysmal arrhythmia (3), to persistent atrial arrhythmia (4).
📍Atrial failure: End-stage AtCM, characterized by persistent AF or HF with symptoms attributable to atrial disease.
📍Early recognition matters! Risk factor & comorbidity management may help prevent or delay progression to atrial failure.
Read more in #EJHF @EJHFEiC 🔗 doi.org/10.1002/ejhf.3782
@escardio @h_arfsten @GTersalvi @jozinetm
So the final analysis for the pivot pivotal preservative is in, and it looks like adjuvant pembrolizumab shows promise for high-risk ccRCC patients!.
Final analysis of the pivotal KEYNOTE-564 trial in #KidneyCancer presented by @DrChoueiri at #ESMO26. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
CC: @DanaFarber_GU
Liam Brown retweeted
Oncology fellows: share your genitourinary cancer research with peers and leading GU faculty at the OncLive® National Fellows Forum, Feb 10, 2027, in San Francisco. Abstracts due Dec 31.
Submit your abstract: hubs.li/Q04C9f9W0
#pcsm #blcsm #kcsm
Liam Brown retweeted
📰Just in: T-cell–redirecting therapies continue to demonstrate improvements in early-relapse myeloma.
Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology
onclive.com/view/elranatamab…
))- ))-))-)---))) ))-))-)))-))-)) ))) )))) )- )) )) ))- )--)) )--))-)))))))))-))- )) )--))-)- )))))))))) ))-)-)) )))))-)))))-))-))))))- ))-
#demencia
Liam Brown retweeted
Should we test for Alzheimer's disease before symptoms begin? What resonates with me about this thoughtful JAMA Viewpoint by neurologist Gayatri Devi is the important reminder that just because we can test for Alzheimer's disease does not always mean we should. We are entering an exciting era when blood tests can detect Alzheimer's-related proteins years before memory problems appear, but what do we tell someone who tests positive and may never develop dementia? The article highlights a striking finding: in adults younger than 60 without symptoms, the positive predictive value of one blood biomarker test for detecting amyloid pathology dropped to just 38%. A positive test could create enormous anxiety, affect long-term care or life insurance, and turn an otherwise healthy person into what the author calls a patient-in-waiting. I believe strongly in early detection, and I am excited about the possibility of preventing Alzheimer's before symptoms begin, but we must distinguish detecting abnormal proteins from predicting who will actually develop dementia. Until we have better tools to predict individual risk and proven preventive treatments, we should be cautious about routine testing of folks without symptoms. In the meantime, we already have meaningful actions we can recommend, including exercise, better sleep, controlling blood pressure, addressing hearing loss and staying socially engaged. The goal of medicine should not simply be to identify disease earlier, but to help folks live longer, healthier and better lives.
cutt.ly/eyRxDMsO
Liam Brown retweeted
Sugerencias básicas para el cuidado de una persona que padece #demencia.
Infografía sobre #SaludMental en colaboración con la psiquiatra Blanca Bolea del @WCHospital para en programa de radio en @chha1610am y su periodista @heyyousilvia
Liam Brown retweeted
Belaid et al report the largest single-country cohort of RAG1/2 deficiency (n=128, Algeria). 2 founder variants explain 77% of cases, yet identical genotypes produced 3 different phenotypes. Mortality (89%) reflected transplant access, not diagnostic delay hubs.la/Q04Cjrmw0
Uncertainty around these products' sources, contamination risk, and potential displacement of approved treatments are all concerns that clinicians should address with patients.
💬 Viewpoint by Sophia Samantaroy, MS, Isabella Xu, MPH, and Peter Lurie, MD, MPH: Proposed expansion of access to compounded #Peptides may have implications for patient safety and clinical practice because these products are not subject to the same requirements as FDA-approved drugs.
Clinicians may see increasing patient demand, should ask about peptide use, and should counsel patients about uncertain sources, contamination risk, and displacement of approved treatments.
ja.ma/4i6FhZI
Catching it early is crucial for effective treatment!.
What Is Molecular Progression, and Why Catch It Early?
▶️ Watch the full Episode 10 on YouTube - youtu.be/5Z7a3HkDsG4?si=ALjh…
🎧 Listen on Spotify, Apple Podcasts, Amazon Music, CastBox & iHeartRadio - linkin.bio/breastfriendspodc…
🎙@JAMouabbi @PTarantinoMD @CHMediaHub
Sweet! It looks like a new study in critical care has been published, focusing on preventing weaning failure in high-risk patients with the PRIVENT program!.
🌬️New in #CriticalCare:
A specialist-led interprofessional weaning program to prevent weaning failure in high-risk patients: the PRiVENT study
doi.org/rt8q
#CritCare #Weaning #PRiVENT
